逍遥散对肝纤维化模型大鼠肝功能、肝纤维化指标的影响
|
摘要
目的:观察逍遥散对肝纤维化模型大鼠的肝功能、肝纤维化指标的影响。方法:选取清洁级成年Wistar大鼠80只,采用随机数字表法分为空白组(等量生理盐水)、模型组(等量生理盐水)、阳性对照组(秋水仙碱)、逍遥散低剂量组(1 g·mL~(-1)的逍遥散溶液,按照8 g·kg~(-1)灌胃)、逍遥散高剂量组(1 g·mL~(-1)的逍遥散溶液,按照16 g·kg~(-1)灌胃),均连续给药8周。结果:干预8周后,逍遥散高剂量组大鼠血清丙氨酸氨基转移酶(alanine aminotransferase,ALT)、天门冬氨酸氨基转移酶(aspartate aminotransferase,AST)水平均低于阳性对照组和逍遥散低剂量组(P<0.05),白蛋白(albumin,ALB)高于阳性对照组和逍遥散低剂量组(P<0.05)。逍遥散高剂量组的血清透明质酸(hyaluronic acid,HA)、层黏蛋白(laminin,LN)、Ⅲ型前胶原(precollagen typeⅢ,PCⅢ)、Ⅳ型胶原(collagen typeⅣ,Ⅳ-C)水平低于阳性对照组和逍遥散低剂量组(P<0.05)。逍遥散高剂量组的转化生长因子β1(transforming growth factor-β1,TGF-β1)、血小板衍生生长因子(platelet-derived growth factor,PDGF)蛋白表达水平低于阳性对照组和逍遥散低剂量组(P<0.05)。结论:逍遥散能显著改善肝纤维化模型大鼠肝功能(降低ALT、AST水平)和血清肝纤维化指标(降低HA、LN、PCⅢ及Ⅳ-C水平),降低肝组织中TGF-β1及PDGF蛋白表达水平。
Objective:To observe the effects of Xiaoyao Powder on liver function and liver fibrosis in rats with liver fibrosis.Methods:Eighty adult Wistar rats were randomly divided into a blank group(equal saline),a model group(equal saline),a positive control group(colchicine treatment),and a low volume.The Xiaoyao Powder low dose group(1 g·mL~(-1) Xiaoyao Powder) solution gavage was carried out with 8 g·kg~(-1),while Xiaoyao Powder high dose group(1 g·mL~(-1) Xiaoyao Powder) solution gavage was carried with 16 g·kg~(-1).The drug was administered continuously for 8 weeks.RESULTS:After 8 weeks of intervention,the serum levels of alanine aminotransferase(ALT) and aspartate aminotransferase(AST) in the high dose group of Xiaoyao Powder were lower than those of the positive control group and Xiaoyao Powder low dose group(P<0.05),while albumin(ALB) was higher than the positive control group and Xiaoyao Powder low dose group(P<0.05).Serum hyaluronic acid(HA),laminin(LN),type Ⅲ procollagen(precollagen type Ⅲ,PCⅢ),type Ⅳ collagen(collagen type Ⅳ,Ⅳ-C) levels in high-dose group.It was lower than the positive control group and Xiaoyao Powder low dose group(P<0.05).The expression levels of transforming growth factor-β1(TGF-β1) and platelet-derived growth factor(PDGF) in the high-dose group were lower than those in the positive control group and Xiaoyao Powder low-dose group(P<0.05).Conclusion:Xiaoyao Powder can significantly improve liver function(reduced ALT,AST level) and serum fibrosis index(reduced HA,LN,PCⅢ and Ⅳ-C levels) in liver fibrosis model rats,and reduce TGF-β1 in liver tissue as well as PDGF protein expression level.
Objective:To observe the effects of Xiaoyao Powder on liver function and liver fibrosis in rats with liver fibrosis.Methods:Eighty adult Wistar rats were randomly divided into a blank group(equal saline),a model group(equal saline),a positive control group(colchicine treatment),and a low volume.The Xiaoyao Powder low dose group(1 g·mL~(-1) Xiaoyao Powder) solution gavage was carried out with 8 g·kg~(-1),while Xiaoyao Powder high dose group(1 g·mL~(-1) Xiaoyao Powder) solution gavage was carried with 16 g·kg~(-1).The drug was administered continuously for 8 weeks.RESULTS:After 8 weeks of intervention,the serum levels of alanine aminotransferase(ALT) and aspartate aminotransferase(AST) in the high dose group of Xiaoyao Powder were lower than those of the positive control group and Xiaoyao Powder low dose group(P<0.05),while albumin(ALB) was higher than the positive control group and Xiaoyao Powder low dose group(P<0.05).Serum hyaluronic acid(HA),laminin(LN),type Ⅲ procollagen(precollagen type Ⅲ,PCⅢ),type Ⅳ collagen(collagen type Ⅳ,Ⅳ-C) levels in high-dose group.It was lower than the positive control group and Xiaoyao Powder low dose group(P<0.05).The expression levels of transforming growth factor-β1(TGF-β1) and platelet-derived growth factor(PDGF) in the high-dose group were lower than those in the positive control group and Xiaoyao Powder low-dose group(P<0.05).Conclusion:Xiaoyao Powder can significantly improve liver function(reduced ALT,AST level) and serum fibrosis index(reduced HA,LN,PCⅢ and Ⅳ-C levels) in liver fibrosis model rats,and reduce TGF-β1 in liver tissue as well as PDGF protein expression level.
引文
[1]夏海珊,陈少茹,钟月春,等.肝纤维化的发病机制和药物治疗现况[J].中国医药导报,2014,18(18):162-165,168.
[2]范慧宁,陈尼维.肝纤维化的流行病学研究进展[J].国际消化病杂志,2014,34(1):29-31,47.
[3]张梦然,成军.肝纤维化研究进展[J].国际消化病杂志,2014,5(6):374-379.
[4]阎晶璐,薛晓兴,李君玲,等.肝纤维化肝气郁结证大鼠模型研究与证候时间窗方剂验证[J].北京中医药大学学报,2016,39(11):893-901.
[5]叶静,刘清华,王璐璐,等.抗肝纤维化药物治疗的研究进展[J].山东医药,2014,21(42):101-103.
[6]毛忠懿,吴雄健,陶立刚,等.ILK 和 TGF-β1在实验性大鼠肝纤维化中的表达和意义[J].安徽医药,2014,9(9):1630-1633.
[7]王云莲,艾力江·吐尔逊,艾尼瓦尔·艾木都拉,等.结缔组织生长因子在放射性肝纤维化大鼠中的动态表达及其与肝星状细胞活化的关系[J].中华放射医学与防护杂志,2014,34(10):748-752.
[8]REITER R,FREISE C,JHRENS K,et al.Wideband MRE and static mechanical indentation of human liver specimen:Sensitivity of viscoelastic constants to the alteration of tissue structure in hepatic fibrosis[J].J Biomech,2014,47(7):1665-1674.
[9]徐韶凯,党晓卫.抗凝治疗与肝纤维化研究进展[J].中华实验外科杂志,2016,33(4):1163-1165.
[10]安纪红,倪文,乔杰,等.中药治疗慢性乙型肝炎肝纤维化的疗效观察及生存质量研究[J].中华肝脏病杂志,2014,22(1):30-32.
[11]林利静,陈高峰,顾宏图,等.FibroScan评判中医药抗肝纤维化疗效的价值[J].中华肝脏病杂志,2014,22(2):113-117.
[12]王业秋,任燕冬,刘海洋,等.逍遥散抗大鼠肝纤维化活性部位的筛选[J].中医药学报,2014,3(3):141-143.
[13]陈斌,徐嘉蔚,彭杰,等.基于逍遥散及其拆方研究“肝病实脾法”对肝纤维化大鼠肠道菌群的影响[J].临床肝胆病杂志,2016,32(4):657-662.
[14]RUCHI B,JAI P,MARIEKE D R,et al.Interferon gamma peptidomimetic targeted to hepatic stellate cells ameliorates acute and chronic liver fibrosis in vivo[J].J Control Release,2014,179:18-24.
[15]马红,徐小元.中华医学会肝病学分会第四次全国肝纤维化、肝硬化学术会议会议纪要[J].中华肝脏病杂志,2015,23(2):146.
[16]王付,尚立芝,苗小玲,等.四逆散加味对肝纤维化大鼠肝功能、肝纤维化指标及病理变化的影响[J].中国实验方剂学杂志,2012,18(5):177-180.
[2]范慧宁,陈尼维.肝纤维化的流行病学研究进展[J].国际消化病杂志,2014,34(1):29-31,47.
[3]张梦然,成军.肝纤维化研究进展[J].国际消化病杂志,2014,5(6):374-379.
[4]阎晶璐,薛晓兴,李君玲,等.肝纤维化肝气郁结证大鼠模型研究与证候时间窗方剂验证[J].北京中医药大学学报,2016,39(11):893-901.
[5]叶静,刘清华,王璐璐,等.抗肝纤维化药物治疗的研究进展[J].山东医药,2014,21(42):101-103.
[6]毛忠懿,吴雄健,陶立刚,等.ILK 和 TGF-β1在实验性大鼠肝纤维化中的表达和意义[J].安徽医药,2014,9(9):1630-1633.
[7]王云莲,艾力江·吐尔逊,艾尼瓦尔·艾木都拉,等.结缔组织生长因子在放射性肝纤维化大鼠中的动态表达及其与肝星状细胞活化的关系[J].中华放射医学与防护杂志,2014,34(10):748-752.
[8]REITER R,FREISE C,JHRENS K,et al.Wideband MRE and static mechanical indentation of human liver specimen:Sensitivity of viscoelastic constants to the alteration of tissue structure in hepatic fibrosis[J].J Biomech,2014,47(7):1665-1674.
[9]徐韶凯,党晓卫.抗凝治疗与肝纤维化研究进展[J].中华实验外科杂志,2016,33(4):1163-1165.
[10]安纪红,倪文,乔杰,等.中药治疗慢性乙型肝炎肝纤维化的疗效观察及生存质量研究[J].中华肝脏病杂志,2014,22(1):30-32.
[11]林利静,陈高峰,顾宏图,等.FibroScan评判中医药抗肝纤维化疗效的价值[J].中华肝脏病杂志,2014,22(2):113-117.
[12]王业秋,任燕冬,刘海洋,等.逍遥散抗大鼠肝纤维化活性部位的筛选[J].中医药学报,2014,3(3):141-143.
[13]陈斌,徐嘉蔚,彭杰,等.基于逍遥散及其拆方研究“肝病实脾法”对肝纤维化大鼠肠道菌群的影响[J].临床肝胆病杂志,2016,32(4):657-662.
[14]RUCHI B,JAI P,MARIEKE D R,et al.Interferon gamma peptidomimetic targeted to hepatic stellate cells ameliorates acute and chronic liver fibrosis in vivo[J].J Control Release,2014,179:18-24.
[15]马红,徐小元.中华医学会肝病学分会第四次全国肝纤维化、肝硬化学术会议会议纪要[J].中华肝脏病杂志,2015,23(2):146.
[16]王付,尚立芝,苗小玲,等.四逆散加味对肝纤维化大鼠肝功能、肝纤维化指标及病理变化的影响[J].中国实验方剂学杂志,2012,18(5):177-180.